448 related articles for article (PubMed ID: 33895749)
1. Successful Treatment with Belimumab in a Patient with Refractory Systemic Lupus Erythematosus after Initiation of Hemodialysis: Considering the Synergistic Effect of Belimumab and Immunological Burn-Out Phenomenon in End-Stage Renal Disease Patients on Hemodialysis.
Karasawa K; Ogura S; Takabe T; Miyabe Y; Iwabuchi Y; Akiyama K; Sato M; Moriyama T; Uchida K; Nitta K
Blood Purif; 2022; 51(2):182-188. PubMed ID: 33895749
[TBL] [Abstract][Full Text] [Related]
2. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
Staveri C; Karokis D; Liossis SC
Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
van Schaik M; Arends EJ; Soonawala D; van Ommen E; de Leeuw K; Limper M; van Paassen P; Huizinga TWJ; Toes REM; van Kooten C; Rotmans JI; Rabelink TJ; Teng YKO
Trials; 2022 Nov; 23(1):939. PubMed ID: 36371234
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of belimumab in central nervous system demyelinating syndromes with systemic lupus erythematosus: A case series.
Liu Y; Fan Q; Jia C; Wan Q; Yang H
Medicine (Baltimore); 2023 Jun; 102(25):e34079. PubMed ID: 37352070
[TBL] [Abstract][Full Text] [Related]
5. Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.
Furer V; Zisman D; Pokroy-Shapira E; Molad Y; Elkayam O; Paran D
Scand J Rheumatol; 2016; 45(2):103-6. PubMed ID: 26515057
[TBL] [Abstract][Full Text] [Related]
6. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
[TBL] [Abstract][Full Text] [Related]
7. Analysis of lupus activity in end-stage renal disease treated by hemodialysis.
Okano K; Yumura W; Nitta K; Uchida K; Ohnuki T; Kawashima A; Nihei H
Intern Med; 2001 Jul; 40(7):598-602. PubMed ID: 11506299
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy.
Liu D; Zhou Q; Wang D; Qu Y; Guo Q; Wen J; Yu Q; Ai J
Lupus; 2022 Oct; 31(12):1456-1467. PubMed ID: 35960182
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the treatment of systemic lupus erythematosus with belimumab in children.
Deng WP
Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1069-1074. PubMed ID: 34719425
[TBL] [Abstract][Full Text] [Related]
10. Belimumab for the treatment of pediatric patients with lupus nephritis.
Stohl W; Kwok A
Expert Opin Biol Ther; 2023 Mar; 23(3):243-251. PubMed ID: 36750049
[TBL] [Abstract][Full Text] [Related]
11. The use of belimumab in three cases of refractory lupus nephritis.
Malaweera A; Dayan S; Pellicano R; Hoi A; Kitching AR; Kent JR
Intern Med J; 2023 Oct; 53(10):1901-1906. PubMed ID: 37859540
[TBL] [Abstract][Full Text] [Related]
12. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
13. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report.
Danve A; Perry L; Deodhar A
Semin Arthritis Rheum; 2014 Oct; 44(2):195-7. PubMed ID: 25005336
[TBL] [Abstract][Full Text] [Related]
14. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
Iaccarino L; Bettio S; Reggia R; Zen M; Frassi M; Andreoli L; Gatto M; Piantoni S; Nalotto L; Franceschini F; Larosa M; Fredi M; Punzi L; Tincani A; Doria A
Arthritis Care Res (Hoboken); 2017 Jan; 69(1):115-123. PubMed ID: 27390293
[TBL] [Abstract][Full Text] [Related]
15. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
Jones A; Muller P; Dore CJ; Ikeji F; Caverly E; Chowdhury K; Isenberg DA; Gordon C; Ehrenstein MR
BMJ Open; 2019 Dec; 9(12):e032569. PubMed ID: 31848169
[TBL] [Abstract][Full Text] [Related]
16. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
[No Abstract] [Full Text] [Related]
17. Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A case series.
Fan Q; Yang H; Liu Y
Z Rheumatol; 2024 Jun; 83(5):387-392. PubMed ID: 38157053
[TBL] [Abstract][Full Text] [Related]
18. Belimumab for systemic lupus erythematosus.
Singh JA; Shah NP; Mudano AS
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD010668. PubMed ID: 33631841
[TBL] [Abstract][Full Text] [Related]
19. Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient).
Binda V; Trezzi B; Del Papa N; Beretta L; Frontini G; Porata G; Fabbrini P; Pozzi MR; Messa P; Sinico RA; Moroni G
J Nephrol; 2020 Oct; 33(5):1019-1025. PubMed ID: 32002799
[TBL] [Abstract][Full Text] [Related]
20. Effect and safety profile of belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus.
Nakai T; Fukui S; Kidoguchi G; Ikeda Y; Kitada A; Nomura A; Tamaki H; Kishimoto M; Okada M
Clin Rheumatol; 2022 Dec; 41(12):3735-3745. PubMed ID: 35939162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
